SynthesisPsychiatry and clinical neurosciences2024
Impact of psilocybin on cognitive function: A systematic review.
Synthesis in Psychiatry and clinical neurosciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effects of LSD, DMT and psilocybin on cognitive and psychological functions: A systematic review of the literature.Journal of psychopharmacology (Oxford, England) · 2026Pooled it
- The subtle science: a systematic review of psilocybin magic mushroom and truffle microdosing.Frontiers in psychiatry · 2026Pooled it
- Psilocybin modulates social behaviour in male and female mice in a time-dependent manner.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Psychedelic Drugs Rediscovered-In Silico Study of Potential Fetal Exposure to Analogues of Psychedelic Drugs During Pregnancy.Molecules (Basel, Switzerland) · 2026Article
- Elevated serotonin receptor 2A signaling restores learning and memory in a Fragile X syndrome model.Scientific reports · 2026Article
- Cognition in Treatment-Resistant Depression: Obstacles and Challenges?Advances in experimental medicine and biology · 2026Review
- Case Report: Repeated low doses of psilocybin reduce perceived symptom severity but fail to restore cognitive flexibility in a case of severe obsessive-compulsive disorder: an observational case study of identical twins.Frontiers in psychiatry · 2026Article
- Psychedelics and the Serotonin Hypothesis of Eating Disorders.Brain sciences · 2025Review
- Review
- Psilocybin-assisted psychotherapy for Parkinson's disease without depression: A case-report.Journal of Parkinson's disease · 2025Article
- Advances in Psychoactive Alkaloid Delivery, Ergoline Analogues, and Serotonin Receptor Modulation for Enhanced Therapeutic Outcomes.ACS medicinal chemistry letters · 2025Article
- Clinical conceptualisation of PTSD in psilocybin treatment: disrupting a pre-determined and over-determined maladaptive interpretive framework.Therapeutic advances in psychopharmacology · 2025Review
- Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024.F1000Research · 2025Article
- Public psychology and holistic approaches to prevention and treatment of depression.Frontiers in psychiatry · 2025Article
- Advances in Psychedelic Therapeutics: Novel Prodrugs and Derivatives for Enhanced Mental Health Treatment.ACS medicinal chemistry letters · 2024Article
- Advanced Delivery Systems and Novel Psilocin Derivatives for Enhanced Therapeutic Applications.ACS medicinal chemistry letters · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psilocybin is a classic psychedelic with demonstrated preliminary clinical efficacy in a range of psychiatric disorders. Evaluating the impact of psilocybin on cognitive function is essential to unravel its potential benefits and risks. In this systematic review, we assessed psilocybin's effect on cognitive function through a comprehensive search of electronic databases from inception to January 2024, identifying 20 articles involving 2,959 participants. While 85% of studies were conducted in healthy volunteers, most of these studies (85%) used macrodoses, ranging from 45 μg/kg to 30 mg/70 kg. Various cognitive aspects were evaluated and yielded mixed results. Global cognitive function, and processing speed remained mostly unchanged in healthy individuals; However, a limited number of studies reported improvements in certain areas such as sustained attention, working memory, and executive function especially in patients with treatment-resistant depression (TRD). Emotional processing was positively modified, particularly in TRD patients. Psilocybin was observed to enhance emotional empathy without significantly altering cognitive empathy and social cognition. Cognitive flexibility and creative cognition were noted to initially decline but could potentially improve over time. Additionally, with respect to learning and memory skills, psilocybin showed promise in improving specific memory types such as semantic associations and associative learning, while its effects on episodic and verbal memory have been less pronounced compared to other cognitive enhancers. The observed mixed findings underscore the complexity of psilocybin's cognitive influence. Further research is essential to provide a clearer understanding of psilocybin's impact on cognitive domains and to guide the development of safe and effective interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.